BCL2 and follicular lymphoma: With the previous data of acquired resistance to VTX due to Phe104 mutations [133], the Phe104Ile mutation was detected in a patient with relapsed/refractory follicular lymphoma (FL) treated with BCL-2 inhibitor, which lessened the binding of VTX to BCL-2 by approximately 40-fold [127].